MA42458A - Systèmes améliorés d'administration de nanoparticules - Google Patents

Systèmes améliorés d'administration de nanoparticules

Info

Publication number
MA42458A
MA42458A MA042458A MA42458A MA42458A MA 42458 A MA42458 A MA 42458A MA 042458 A MA042458 A MA 042458A MA 42458 A MA42458 A MA 42458A MA 42458 A MA42458 A MA 42458A
Authority
MA
Morocco
Prior art keywords
delivery systems
nanoparticle delivery
improved nanoparticle
improved
systems
Prior art date
Application number
MA042458A
Other languages
English (en)
Inventor
Winnie Lui
Lawrence Mayer
Paul Tardi
Leon Wan
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of MA42458A publication Critical patent/MA42458A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA042458A 2015-07-15 2016-07-14 Systèmes améliorés d'administration de nanoparticules MA42458A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US201562252396P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
MA42458A true MA42458A (fr) 2018-05-23

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042458A MA42458A (fr) 2015-07-15 2016-07-14 Systèmes améliorés d'administration de nanoparticules

Country Status (17)

Country Link
US (4) US10285951B2 (fr)
EP (1) EP3322404A4 (fr)
JP (2) JP2018521068A (fr)
KR (1) KR20180029242A (fr)
CN (1) CN107920985B (fr)
AU (2) AU2016294617B2 (fr)
BR (1) BR112018000217A2 (fr)
CA (1) CA2991062C (fr)
CO (1) CO2018000146A2 (fr)
HK (1) HK1251159A1 (fr)
IL (1) IL256797B (fr)
MA (1) MA42458A (fr)
MX (1) MX2018000611A (fr)
RU (1) RU2018105494A (fr)
SG (1) SG10201912394VA (fr)
WO (1) WO2017011685A1 (fr)
ZA (1) ZA201800130B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021645A1 (fr) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Ciblage du systeme immunitaire inne pour induire une tolerance a long terme et pour resoudre l'accumulation de macrophages dans l'atherosclerose
JP7357629B2 (ja) * 2017-11-20 2023-10-06 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノバイオロジー組成物での訓練された免疫の阻害
US20210023017A1 (en) * 2018-03-16 2021-01-28 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
KR102088663B1 (ko) * 2018-03-20 2020-03-13 한국세라믹기술원 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
WO2020123481A1 (fr) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Formulations combinées de taxanes et d'inhibiteurs de mtor
CN114401736A (zh) * 2019-08-13 2022-04-26 佩蒂诺沃生物制药公司 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm
EP4211144A1 (fr) * 2020-09-11 2023-07-19 Nammi Therapeutics, Inc. Compositions liposomales formulées et/ou co-formulées contenant des promédicaments antagonistes de pd-1 utiles dans le traitement du cancer et méthodes associées
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2025199353A1 (fr) * 2024-03-21 2025-09-25 Purdue Research Foundation Formulations nanoparticulaires et leur administration foliaire dans le traitement et la prévention de la maladie du dragon jaune

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432402B1 (fr) * 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Compositions pour l'administration de combinaisons medicinales
EP1448231A1 (fr) * 2001-11-19 2004-08-25 Control Delivery Systems, Inc. Administration topique de medicaments combines
EP1603391A4 (fr) 2003-02-20 2009-06-24 Univ Connecticut Health Ct Methodes d'utilisation de compositions contenant des proteines du stress ou une macroglobuline alpha-2 dans le traitement de cancer et de maladie infectieuse
JP2008506780A (ja) 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク. 活性剤放出のための粒子状構築物
CA2603987A1 (fr) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Composition micellaire polymere et medicament contenu dans celle-ci
EP2222278B1 (fr) * 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Système d'administration de taxane amélioré
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
WO2011060328A1 (fr) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, et procédés pour l'identification, l'évaluation, la prévention, et la thérapie d'un cancer
MX2013002051A (es) * 2010-08-20 2013-06-28 Cerulean Pharma Inc Particulas, composiciones y conjugados de peptido terapeutico-polimero y metodos relacionados.
US20130231347A1 (en) 2010-11-19 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
US9987354B2 (en) * 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (de) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Stuhl mit Wippmechanik
CN106573077B (zh) * 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂

Also Published As

Publication number Publication date
CN107920985B (zh) 2022-03-01
MX2018000611A (es) 2018-09-06
HK1251159A1 (zh) 2019-01-25
CA2991062C (fr) 2023-06-20
IL256797B (en) 2021-05-31
ZA201800130B (en) 2018-12-19
RU2018105494A3 (fr) 2019-12-17
JP2018521068A (ja) 2018-08-02
KR20180029242A (ko) 2018-03-20
AU2021286353A1 (en) 2022-01-20
SG10201912394VA (en) 2020-02-27
CO2018000146A2 (es) 2018-04-19
US20180207104A1 (en) 2018-07-26
US10285951B2 (en) 2019-05-14
US11413253B2 (en) 2022-08-16
CA2991062A1 (fr) 2017-01-19
US20240366519A1 (en) 2024-11-07
EP3322404A1 (fr) 2018-05-23
EP3322404A4 (fr) 2019-03-20
IL256797A (en) 2018-06-28
CN107920985A (zh) 2018-04-17
JP2022033751A (ja) 2022-03-02
AU2016294617B2 (en) 2021-09-16
BR112018000217A2 (pt) 2018-09-04
AU2016294617A1 (en) 2018-01-25
US20210052508A1 (en) 2021-02-25
RU2018105494A (ru) 2019-08-15
US20190209484A1 (en) 2019-07-11
WO2017011685A1 (fr) 2017-01-19

Similar Documents

Publication Publication Date Title
EP3322404A4 (fr) Systèmes améliorés d'administration de nanoparticules
EP3373908A4 (fr) Systèmes d'administration de probiotiques
EP2950785A4 (fr) Systèmes d'administration de médicament nanoparticulaires
EP3294398A4 (fr) Systèmes et procédés d'administration de médicaments
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
EP3383456A4 (fr) Systèmes et procédés pour pompes d'administration de médicaments commandée
EP3449274A4 (fr) Systèmes d'imagerie tridimensionnelle
ZA201807048B (en) Medical delivery system
EP3435978A4 (fr) Système d'administration
EP3389557A4 (fr) Système d'administration trans-septale
EP2948896A4 (fr) Système d'administration d'agent bioactif biosynchrone optimisé
EP3402548C0 (fr) Résolution d'occlusion dans des dispositifs, des systèmes et des procédés d'administration de médicaments
EP3589341A4 (fr) Système d'administration de médicament commandé à distance
EP3297620A4 (fr) Système d'administration transdermique de la kétamine
EP3348648A4 (fr) Véhicule d'administration intracellulaire
MA45472A (fr) Systèmes d'administration pour la libération contrôlée de médicaments
EP2962265A4 (fr) Systèmes et procédés d'amélioration de la maintenance de listes de problèmes associés à un patient.
EP3313499A4 (fr) Dispositifs, systèmes et procédés permettant d'améliorer l'absorption et l'administration de médicament par voie intraluminale
SI3265140T1 (sl) Dostavni sistemi za dostavo skozi sluznico ali skozi kožo
EP3302087A4 (fr) Système d'infusion
EP3422911A4 (fr) Systèmes et procédés d'administration d'additif réglable
EP3471699A4 (fr) Systèmes d'administration de muco-adhésifs hybrides.
EP3328361A4 (fr) Nanoparticules de résine chargées de médicament
EP3377080A4 (fr) Peptides à propriétés anti-angiogéniques, anti-lymphangiogéniques, et anti- démiques et formulations de nanoparticules
EP3334413A4 (fr) Dispositif d'administration